As described previously, mutations involved in the Ras signaling pathway (NRAS, KRAS, FLT3, PTPN11, and NF1) occurred in more than half of B-ALL patients [14, 15] . The gene discussed is FLT3; the disease is precursor B-cell acute lymphoblastic leukemia.